吉西他滨代谢酶与胰腺癌化疗耐药关系的研究进展  

Progress in The Relationship Between Metabolic Enzyme of Gemcitabine and Chemotherapeutic Resistance of Pancreatic Cancer

作　　者：袁田[1,2] 廖泉[2] 赵玉沛[2] 

机构地区：[1]中国医学科学院北京协和医学院,北京100730 [2]中国医学科学院北京协和医院基本外科,北京100730

出　　处：《中国普外基础与临床杂志》2009年第8期613-616,共4页Chinese Journal of Bases and Clinics In General Surgery

基　　金：国家自然科学基金(项目编号:30772526)~~

摘　　要：目的介绍吉西他滨代谢酶对胰腺癌化疗耐药影响的研究进展。方法复习和总结了近年来的相关文献,对吉西他滨代谢酶与胰腺癌化疗耐药关系的研究进展加以综述。结果hENT1、dCK、RRM1、CDA等代谢酶与胰腺癌对吉西他滨化疗的耐药具有密切关系;代谢酶的单核苷酸多态性与胰腺癌对吉西他滨耐药的关系仍有待研究。结论胰腺癌对吉西他滨化疗耐药是多因素、多因子共同作用的结果,对于代谢酶影响胰腺癌化疗耐药的机理有待进一步研究。Objective To introduce the research progress in the effect of chemotherapeutic resistance of metabolic enzymes of gemcitabine to pancreatic cancer. Methods Recent literatures about metabolic enzymes that played key roles in mediating gemcitahine chemotherapeutic resistance of pancreatic cancer were collected and reviewed. Resuits The metabolic enzymes of gemcitabine, such as hENT1, dCK, RRM1 and CDA, were closely related to che- motherapeutic resistance of pancreatic cancer. The relationship between the single nucleotide polymorphism of metabolic enzymes and the resistance to gemcitabine remained to be clarified. Conclusion Multiple factors are involved in the mechanism of chemotherapeutic resistance of pancreatic cancer to gemcitabine, which needs further research.

关 键 词：胰腺癌 吉西他滨 代谢酶 耐药性 化疗 

分 类 号：R735.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]